Associate Professor

Phone: 027-83692745

Email: shwgong@ hust.edu.cn or shwgong2013@yahoo.com

Academic Areas:Pharmaceutical affairs management, Pharmacy policy and pharmacy economics

Research Interests:

Academic Degrees

Professional Experience

Selected Publications

1. Gong Shiwei; Wang Yingxiao; Pan Xiaoyun; Zhang Liang; et al. The availability and affordability of orphan drugs for rare diseases in China. Orphanet Journal of Rare Diseases, 2016(   11   ): 20. (SCI, A)

2. Xiong Xiaolei，Gong Shiwei. Relationship between industrial pollutant emissions and inpatient utilization among respiratory disease patients in China. Chin J Public Health， 2016,32(9):1203-1206.

3. Chen Xin，Xiong Xiaolei，Gong Shiwei. Comparative analysis ofgovernment sponsored research fund projects of rare diseases and orphan drugs between China and USA. Chin Hosp Pharm Ｊ,2016,36(12):961-963, 1002.

4. Wang Chen, Yin Jia, Zhang Jinwen, Gong Shiwei. Meta Analysis on Use Rate of Antibiotics in Outpatient Prescriptions of Primary Hospitals before and after the Implementation of Essential Drug Policy. China Pharmacist, 2016, 19(4):721-725.

5. Hu Juanjuan, Chen Xin, Gong Shiwei. Selection Principle of Orphan Drug Under UK，Canada and Australia National Health Service Security System. Medicine and Society, 2016,29(1):10-12,16.

6. Lin Zheren, Hu Juanjuan,Xu Huifang，Gong Shiwei. Literature analysis on Essential Drug Use. Herald of Medicine, 2016,35(6):674-677.

7. Chen Xin, Gong Shiwei. Analysis on Productivity of Biopharmaceutical Industrial Agglomeration Based on the Panel Data of 29 Provinces in China. CHINA HEALTH INDUSTRY, 2016,13(9):28-32.

8. Zhang Ya, Han Xiaojue, Gong Shiwei. Analysis of Pharmacovigilance System of China Based on a Perspective of WHO Pharmacovigilance System Framework. Chin J Pharmacoepidemio, 2016,11:725-730.

9. Hu Juanjuan, Chen Xin, Luo Anqi, Gong Shiwei. Analysis on Reimbursement Level of Orphan Drugs in the Medicare Part D Prescription Drug Plans in the U.S. . Chinese Health Economics, 2015, 34(8):71-73.

10. Xiong Xiaolei, Gong Shiwei. Analysis on FDA’s Functions in Emergency Preparation for Medical Countermeasures. CHINESE PHARMACEUTICAL AFFAIRS, 2015, (1):83-88.

11. Chen Xin, Hu Juanjuan, Gong Shiwei. Assessment of the US strategic national stockpile for medicine from the perspective of the supply chain and implications for China. Chinese Journal of Health Policy, 2014, (9):54-60.

12. Shiwei Gong, Si Jin. Current Progress in the Management of Rare Diseases and Orphan Drugs in China. Intractable & Rare Diseases Research .2012. ( Invited paper).

13. Lin lin Li, Shiwei Gong. The Research Contents and Trends of Pharmaceutical Care in China. Chinese Journal of Hospital Pharmacy，2012，32（2）：147-150.

14. Yi Xu, Yingxiao Wang, Shiwei Gong ^#. Research on Orphan Drug Sales Model of Specialty Pharmacy in U.S. Chinese Pharmaceutical Affairs,2011,25（12）:1238-1241. (Invited paper)，^# Corresponding author.

15. Shiwei Gong. The Experiences of Orphan Drug Management in Some Countries. Health Newspaper. 2011-10-25,005. (Invited paper).

16. Shiwei Gong, Zhigang Li, Yi Xu, Liang Zhang. An Analysis on Regional Discrepancy of Medical and Health Resources Distribution in Terms of Health Accessibility View in China. Chin J Hosp Admin, 2011,27 (5)：315-318.

17. Shiwei Gong, Yi Xu, Liang Zhang. Study on Evaluation Indicator System of Drug Accessibility. Chinese Health Economics, 2011,30（5）: 72-74.

18. Shiwei Gong, Liang Zhang. Analysis of the Demand Characteristics of Inpatient’s Medical care of Common Diseases and Rare Diseases in China. Chinese Health Economics, 2011,30(2):39-41.

19. Qiang Chen, Weiyin Shen, Shi-wei Gong . Analysis on 240 Cases of Antimicrobial Prophylaxis Use in the Perioperative period. China Pharmacist. 2011,14(2): 220-222.

20. Shiwei Gong, Weiyin Shen. Analysis on Management Issues of Rational Use of Antimicrobial Prophylaxis. Medicine and Society, 2011，24（1）：1-3.

21. Jing-Bo Wang, Jeff J Guo, Li Yang, et al. Rare diseases and legislation in China. The Lancet. London: Feb 27-Mar 5, 2010. Vol. 375, 708-709.（Shi-Wei Gong is an acknowledged non-author, but she provided us with valuable information about rare diseases in China）

Awards and Honors

1. 2014.1-2018.12，Assessing geographic and spatial distribution of emergency medicines and modeling pharmaceutical supplies for emergency preparedness in China. Funded by National Natural Science Foundation of China (NSFC No. 71373089). Principal investigator.

2.2010.1-2012.12   Policy option mechanisms on improving accessibility to orphan drug in China. Funded by National Natural Science Foundation of China (NSFC No.70903025). Principal investigator.

3.2008.12-2010.12  Determinant factors of orphan drug availability for rare disease patients and incentive policy in China. Innovation Research Fund for Young faculty of Huazhong University of Science and Technology（Q20090411）. Principal investigator.

4.2005.3-2006.3  Pharmacoeconomics application in China: The application overview of pharmacoeconomics in the field of health insurance in North America. Funded by Ministry of Human Resources and Social Security of the People’s Republic of China, Investigator.

5.2012.1-2015.12   Study on the regression model of transparent measurement of essential drug using in primary health care institutions based on transparency-oriented in China. (NSFC No. 71173082). Second Principal investigator.

Courses Taught

1.Pharmaceutical administration;

2.PharmacoEthics;

3.Commercial law.